originmetrics.com

Sunday, October 5, 2008

Fannie Mae, a housing mortgage lender, has forgiven the mortgage debt of Addie Polk, a 90-year-old woman from Akron, Ohio who attempted to kill herself when she was being evicted from her home on Wednesday.

Polk had lived in her home since 1970, and refinanced her mortgage numerous times since 1997 when she first got a loan taken out against her home. When authorities tried to evict her, she shot herself once in the chest. Fannie Mae took over Polk’s home in 2007 after the loan company filed for foreclosure. One report from Reuters states that authorities tried to evict Polk more than 30 other times in the past.

“Just given the circumstances, we think it’s appropriate,” said Brian Faith, a spokesman for Fannie Mae who also said that the incident was almost immediately “on [their] radar screen”.

Polk is currently undergoing treatment at Akron General Medical Center and is expected to make a full recovery. She can return to her home as soon as she recovers from her injuries.

Polk was recognized on Friday when Dennis Kucinich, who is a democratic representative for Ohio, spoke of her incident during debates on a 700 billion USD bailout bill that the United States House of Representatives passed on Friday. He states that the bill does not focus on people in situations like Polk.

“This bill does nothing for the Addie Polks of the world. This bill fails to address the fact that millions of homeowners are facing foreclosure, are facing the loss of their home. This bill will take care of Wall Street, and the market may go up for a few days, but democracy is going downhill,” said Kucinich on Friday.

Friday, September 22, 2006

The upcoming 2006 Mississauga municipal election, to be held November 13, features an array of candidates looking to represent their wards in city council.

Wikinews contributor Nicholas Moreau has contacted as many candidates as possible, including Tony Ciufo, asking them to answer common questions sent in an email. There is no incumbent in the newly created ward; the sixteen resident competing for the position are Shah Rukh Alam, John Briers, Jamie Dookie, Dale D’Souza, Prag Euclid, Adnan Hashmi, Elias Hazineh, Jack Janiak, Fasal Javaid, Craig Lawrence, Sue M. McFadden, Patrick Mendes, Barbara Polis, Graziano Roti, Ali Tahmourpour, and Scott Wilson.

Saturday, November 15, 2008

Scotland has refused bail to the Libyan man convicted of the bombing of Pan Am Flight 103 despite his terminal cancer, as he can receive treatment in prison. Abdelbaset Ali Mohmed Al-Megrahi was jailed in 2001 for the 1988 bombing of the transatlantic airliner, killing 270 people, but is seeking to have his conviction overturned.

Minutes after Edinburgh’s Appeals Court rejected bail on compassionate grounds Jim Swire, spokesman for the victim’s families who lost his daughter in the disaster, complained about the ruling. “It has never been a goal of our group to seek revenge,” said a lawyer outside the court reading from his statement. “The refusal of a return to his family for a dying man whose verdict is not even yet secure looks uncomfortably like either an aspect of revenge — or perhaps timidity.”

Al-Megrahi, a former intelligence officer, is 54 and serving a minimum of 27 years for the bombing. He has advanced prostate cancer which is spreading through his body. His request for bail was rejected by Lord Hamilton, Scotland’s head judge, who said that as doctors say he could live a few more years he should not be released unless and until after his appeal succeeds or his condition worsens.

Some other doctors give his time as just months, as the cancer has reached his bones. Hamilton however said that palliative hormone treatment could prolong his life. Hamilton also said Al-Megrahi was not suffering “material pain or disability”.

The Scottish Criminal Cases Review Commission ruled last year that the conviction may be a miscarriage of justice. It said there was significant doubts to be raised over several key pieces of evidence in the original trial.

Thursday, June 12, 2008

A large forest fire that started on Monday, June 9 is still out of control in the municipality of Froland in southern Norway. The fire is the largest forest fire to occur in Norway since World War II.

The fire has spread extensively and it is estimated that approximately 2,500 acres of forest have been damaged. Approximately 15 cabins are reported to have burned to the ground, but as of yet, no permanent dwellings or farms have been damaged. However, many inhabitants have been evacuated due to the fire threatening their homes, including the entire villages of Mykland and Belland. There have also been some power outages due to power lines being damaged.

Approximately 140 persons, including fire-fighters from several fire departments, and personnel from the Civil Defence and the Home Guard are working to curtail the fire. Four fire helicopters have been deployed. The fire fighting is focused on areas where the fire threatens buildings.

Extremely dry weather, and difficult wind conditions, have caused severe difficulties in fighting the fire. Fire-fighters first had hope of gaining control on the morning of Thursday, June 12, but the wind changed direction during the day, causing a large extension of the fire. There is some hope that the weekend will bring some rain; however, this will likely not be enough to stop the fire. It could take several weeks before the fire is completely extinguished.

Thursday, September 25, 2008

Medical doctors have not been getting the full picture about newly FDA-approved drugs, concludes a research team from the University of California, San Francisco. This is because not all the studies required for FDA approval get published. New drug studies that do see publication tend to be ones where the medicine appears to perform well while poor and middling results are less likely to appear in medical journals. The result appears to be that doctors who read the available literature may get an inflated impression of new medications and may prescribe expensive new drugs in place of older medicines that perform as well or better. As Jordan Lite of Scientific American wonders, are drug companies cherry-picking the studies they publish to make their drugs look better than they actually are?

The University of California team reviewed trials that had supported new drugs approved from 1998 to 2000 and examined 909 trials of 90 medications. The search was conducted upon PubMed and other search tools that a typical medical doctor or patient could access. They concluded that less than half of the studies had been published five years after drug approval and a publication bias existed.

Erick Turner, who coauthored a similar study earlier this year, expressed concerns to Scientific American that the problem was not merely the raw percentage of studies published, but that a disproportionate share of the research that appeared in journals are examples where new medications appear to perform well:

When trials are selectively published … it will skew the efficacy of the drug and make it look like it works better than it does. It’s going to create a lot more enthusiasm among consumers of that information or in the words of Alan Greenspan, ‘irrational exuberance.’

Ken Johnson, senior vice president of the Pharmaceutical Research and Manufacturers of America (PhRMA), defended the pharmaceutical industry by saying FDA review of new drug applications is more important than publishing the results of medication trials in medical journals. Approved medications come with labels that give patients and doctors enough information, assures Mr. Johnson.

Yet concerns about full and appropriate disclosure have been serious enough that a new law was enacted last year. FDA Amendments Act of 2007 (FDAAA) requires that all trials which support FDA-approved drugs be registered at the National Institutes of Health website. The requirement goes into effect this coming Saturday. Congress enacted the legislation in response to hearings that determined pharmaceutical companies were less likely to publish studies that indicated significant side effects. One shortcoming in the legislation, according to UCSF associate professor Ida Sim, is that the FDA is still not required to specify which trials it weighs when considering applications for drug approvals. Yet she praises the new law as a major improvement. It’s critically important that we know trials exist and that we get the summary results, positive and negative, into the public domain—that’s a huge step and more than any [other] country is doing now.